Alendronate inhibition of protein-tyrosine-phosphatase-meg1

Biochemical Pharmacology

Volumn 54, Issue 6, 1997, Pages 721-727

  Opas, Evan E ^a,b   Rutledge, Su Jane ^a   Golub, Ellis ^b   Stern, Andrew ^c   Zimolo, Zoran ^a,d   Rodan, Gideon A ^a   Schmidt, Azriel ^a  

^a Dept Bone Biol Osteoporosis Res ^*  (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF PENNSYLVANIA SCHOOL OF DENTAL MEDICINE   (United States)

^d YALE UNIVERSITY   (United States)

Author keywords

Alendronate; Bisphosphonate; Osteoporosis; Protein tyrosine phosphatase

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYSTEINE; DITHIOTHREITOL; ETIDRONIC ACID; FLUORESCEIN; INCADRONIC ACID; PAMIDRONIC ACID; PROTEIN TYROSINE PHOSPHATASE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SUBSTRATE COMPLEX; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL;

ALENDRONATE; DNA, COMPLEMENTARY; ENZYME INHIBITORS; HUMANS; PROTEIN-TYROSINE-PHOSPHATASE; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0030776772     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00225-6     Document Type: Article

References (31)

1. Francis MD, Russell RGG and Fleisch H, Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165: 1264-1266, 1969.
2. Kanis JA, Gertz BJ, Singer F and Ortolani S, Rationale for the use of alendronate in osteoporosis. Osteoporos Int 5: 1-13, 1995.
3. Liberman UA, Weiss SR, Broil J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC II, Lombardi A, Shah RV, Hirsch LJ and Karpf DB, Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333: 1437-1443, 1995.
4. Siris E, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A, Lyles K, McIlwain H, Murphy WA Jr, Reda C, Rude R, Seton M, Tiegs R, Thompson D, Tucci JR, Yates AJ and Zimering M, Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 81: 961-967, 1996.
5. c-src tyrosine kinase inhibitor, inhibits osteoclastic bone resorption in vitro and hypercalcemia in vivo. J Clin Invest 91: 2791-2795, 1993.
6. Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu C-T, Huang Z, Ramachandran C, Rodan SB and Rodan GA, Protein-tyrosine phosphatase activity regulates osteoclast formation and function: Inhibition by alendronate. Proc Natl Acad Sci USA 93: 3068-3073, 1996.
7. Soriano P, Montgomery C, Geske R and Bradley A, Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64: 693-702, 1991.
8. c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 90: 1622-1627, 1992.
9. Sato M, Grasser W, Endo N, Atkins R, Simmons H, Thompson DD, Golub E and Rodan GA, Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88: 2095-2105, 1991.
10. Sun H and Tonks NK, The coordinated action of protein tyrosine phosphatases and kinases in cell signaling. Trends Biochem Sci 19: 480-485, 1994.
11. Hunter T, Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling. Cell 80: 225-236, 1995.
12. Møller NPH, Møller KB, Lammers R, Kharitonenkov A, Sures I and Ullrich A, Src kinase associates with a member of a distinct subfamily of protein-tyrosine phosphatases containing an ezrin-like domain. Proc Natl Acad Sci USA 91: 7477-7481, 1994.
13. Gu M, York JD, Warshawsky I and Majerus PW, Identification, cloning, and expression of a cytosolic megakaryocyte protein-tyrosine-phosphatase with sequence homology to cytoskeletal protein 4.1. Proc Natl Acad Sci USA 88: 5867-5871, 1991.
14. Yang Q and Tonks NK, Isolation of a cDNA clone encoding a human protein-tyrosine phosphatase with homology to the cytoskeletal-associated proteins band 4.1, ezrin, and talin. Proc Natl Acad Sci USA 88: 5949-5953, 1991.
15. Endo N, Rutledge SJ, Opas EE, Vogel R, Rodan GA and Schmidt A, Human protein tyrosine phosphatase-σ: Alternative splicing and inhibition by bisphosphonates. J Bone Miner Res 11: 535-543, 1996.
16. Rodan SB, Imai Y, Thiede MA, Wesolowski G, Thompson D, Bar-Shavit Z, Shull S, Mann K and Rodan GA, Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties. Cancer Res 47: 4961-4966, 1987.
17. Bradford MM, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
18. Harder KW, Owen P, Wong LKH, Aebersold R, Clark-Lewis I and Jirik FR, Characterization and kinetic analysis of the intracellular domain of human protein tyrosine phosphatase β (HPTPβ) using synthetic phosphopeptides. Biochem J 298: 395-401, 1994.
19. Duggleby RB, Estimation of the initial velocity of enzyme-catalysed reactions by non-linear regression analysis of progress curves. Biochem J 228: 55-60, 1985.
20. Fleisch H, Bisphosphonates: Mechanisms of Action and Clinical Applications. In: Bone and Mineral Research Annual 1 (Ed. Peck WA), pp. 319-357. Excepta Medica, Amsterdam, 1983.
21. Hughes DE, Mian M, Guilland-Cumming DF and Russell RGG, The cellular mechanism of action of bisphosphonates. Drugs Exp Clin Res 17: 109-114, 1991.
22. Sahni M, Guenther HL, Fleisch H, Collin P and Martin TJ, Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91: 2004-2011, 1993.
23. 3-methylenetetraphosphate). Biochemistry 27: 1897-1901, 1988.
24. Tsuchimoto M, Azuma Y, Higuchi O, Sugimoto I, Hirata N, Kiyoki M and Yamamoto I, Alendronate modulates osteogenesis of human osteoblastic cells in vitro. Jpn J Pharmacol 66: 25-33, 1994.
25. Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugai N, Yamamoto M and Nagata N, Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 18: 9-14, 1996.
26. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ulrich JW, Bilder GE and Perrone MK, Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33: 1657-1663, 1992.
27. Shinozaki T, Watanabe H, Arita S and Chigira M, Amino acid phosphatase activity of alkaline phosphatase. A possible role of protein phosphatase. Eur J Biochem 227: 367-371, 1995.
28. Zhang Z-Y and Dixon JE, Protein tyrosine phosphatases: Mechanism of catalysis and substrate specificity. Adv Enzymol Relat Areas Mol Biol 68: 1-36, 1994.
29. Zhao Z, Bouchard P, Diltz CD, Shen SH and Fischer EH, Purification and characterization of a protein tyrosine phosphatase containing SH2 domains. J Biol Chem 268: 2816-2820, 1993.
30. Lin JH, Bisphosphonates: A review of their pharmacokinetic properties. Bone 18: 75-85, 1996.
31. 3H-etidronate in rat and mouse bones. Bone 19: 281-290, 1996.